News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer.
With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another busy week for cancer drug development news.
The top stories:
The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma.
Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours.
Biopharmaceutical company Syros Pharmaceuticals has announced new clinical data from the Phase I/Ib clinical trial evaluating SY-5609 in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumours.
Lifebit and Flatiron Health have announced a multi-year strategic partnership with the aim of improving scientific discoveries by learning from the experience of cancer patients.
Lynparza (olaparib) has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).